Thailand said on Wednesday that it was still on the way to receive a vaccine for the coronavirus and administered it by the Chinese company Sinovac Biotech starting next month, health officials said, despite data from Brazil’s experience that showed an efficiency of 50.4%.
“There is no impact on our plan at the moment,” said Subakit Cerelac, director general of the Department of Medical Sciences, in a briefing when asked about the Brazil data.
“We are requesting direct information from Sinovac, so we are waiting for their response to get all the facts,” he said.
Thailand, which has reported a total of 10,991 infections and 67 deaths since discovering its first case a year ago, has requested two million doses of coronavirus from Sinovac and expects to receive the first 200,000 doses next month.
It has also ordered 61 million doses of the AstraZeneca vaccine, which will be produced by local company Siam Bioscience for domestic use and export.
The results of the Brazilian experiment came at a time when Indonesia began massive vaccination campaigns against the Corona virus, and its president was the first to receive a Coronavirus vaccination.
Malaysia said on Wednesday that it will only go ahead with the purchase of the Sinovac vaccine if it meets the safety and efficacy standards of local regulators.
The Thai Food and Drug Administration (FDA) said Wednesday that it is evaluating all vaccines on the basis of quality, safety and efficacy.
“Companies requesting approval must provide information that addresses all of these points,” said Deputy Secretary-General of the Food and Drug Administration Surachuki Tangoywat.
Thailand on Tuesday received applications for vaccine registration from AstraZeneca and Sinovac.